For comparison, the peak number of providers prescribing lopinavi

For comparison, the peak number of providers prescribing lopinavir/ritonavir occurred in the 18th quarter, with 1288 of 3861 providers (33.4%) prescribing Inhibitor Library lopinavir/ritonavir. Of the 128 facilities prescribing any antiretrovirals within the VHA, the percentage where each target medication had been prescribed rose quickly over the first five-to-six quarters and then rose gradually over the remaining quarters (Fig. 5). The extent of penetration, however, differed markedly among the

four target medications. By quarter 6, atazanavir had been prescribed at 80% of facilities, closely matching the 83% penetration of lopinavir/ritonavir; darunavir and tipranavir had been prescribed at 65% and 56% of facilities, respectively. By the last quarter of the evaluation period atazanavir and lopinavir/ritonavir had been prescribed at over 95% of all facilities. Similar to overall prescribing of antiretrovirals, Pirfenidone price prescribing of the target medications was greatest at facilities with medium-size HIV practices (Fig. 6). Less than 10% of new prescriptions for target medications in each period occurred at facilities with smaller HIV practice sizes. Prescribing at facilities with large and very large HIV practices was similar to prescribing of all other antiretrovirals. Identification of

whether significant variation in new medication uptake exists across a healthcare system may be important, as such variation may reflect differential patient access to new treatment. Uptake of new antiretrovirals in the VHA generally reflected overall prescribing of all antiretrovirals, suggesting that availability and tuclazepam prescribing of these new agents are consistent across the system. Atazanavir was the most prescribed target antiretroviral and tipranavir the least prescribed within the first year after FDA approval. The peak number of

new prescriptions occurred within the first year after FDA approval for all the medications except darunavir, for which the number of prescriptions continued to rise. All three medications were initially prescribed almost exclusively to antiretroviral-experienced patients. Thus, the early peak uptake probably represents those highly antiretroviral-experienced patients for whom no or limited treatment options existed and who were awaiting the availability of new agents. In addition, an early benefit attributed to atazanavir over other available protease inhibitors or efavirenz was its favourable effect on lipids [14,15]. Thus, some of the early peak uptake in treatment-experienced patients may have occurred in those experiencing significant hyperlipidaemia on other protease inhibitor regimens. After the initial surge of veterans beginning treatment, uptake slowed but remained steady, a trend consistent with what has been reported by others when examining initiation of highly active antiretroviral therapy [16]. Variation in uptake among the targeted antiretrovirals occurred over time.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>